Thrombologic ApS
🇩🇰Denmark
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis
Phase 2
Terminated
- Conditions
- Pneumonia
- Interventions
- Drug: low molecular weight heparin.
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Thrombologic ApS
- Target Recruit Count
- 5
- Registration Number
- NCT01532544
- Locations
- 🇩🇰
University hospital Copenhagen, Copenhagen, Denmark
🇩🇰Vejle hospital, Vejle, Denmark
🇫🇮Kuopio University Hospital, Kuopio, Finland
Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)
Phase 1
Completed
- Conditions
- Myocardial Infarct
- Interventions
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- Thrombologic ApS
- Target Recruit Count
- 16
- Registration Number
- NCT01179776
- Locations
- 🇩🇰
Lene Holmvang, Copenhagen, Denmark
News
No news found